Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056240 | 0.87 | ALDH1A1 (0.48) | PPARGPPARAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL6056303 | 0.86 | PPARG (0.44) | PPARGPPARAALDH1A1HPGD | |
| SCHEMBL6056319 | 0.86 | KDM4E (0.49) | PPARGPPARAFFAR1ALDH1A1 | |
| SCHEMBL21245496 | 0.85 | KDM4E (0.51) | PPARGPPARAMRGPRX4ALDH1A1KMT2A | |
| SCHEMBL6056484 | 0.85 | MAPK1 (0.43) | PPARA | |
| SCHEMBL3124486 | 0.79 | CACNA2D1 (0.40) | PPARGPPARAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL6523909 | 0.79 | CACNA2D1 (0.40) | PPARGPPARAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL1913561 | 0.79 | CACNA2D1 (0.40) | PPARGPPARAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL6056332 | 0.79 | MAPK1 (0.44) | MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL6056264 | 0.78 | KDM4E (0.46) | PPARGPPARASLC1A5MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-1675582-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | Warner-Lambert Company LLC (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005025563-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275469-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | PPARG 2561/4885PPARA 2523/4885SLC1A5 1200/4885 |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | PPARG 2561/4885PPARA 2523/4885SLC1A5 1200/4885 |
| US-11007157-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | PPARG 2561/4885PPARA 2523/4885SLC1A5 1200/4885 |
| US-10588874-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | PPARG 2561/4885PPARA 2523/4885SLC1A5 1200/4885 |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | PPARG 2561/4885PPARA 2523/4885SLC1A5 1200/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | PPARG 2561/4885PPARA 2523/4885SLC1A5 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.